Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis over up to 3 years.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
29 Jan 2024
29 Jan 2024
Historique:
received:
19
12
2023
accepted:
08
01
2024
medline:
29
1
2024
pubmed:
29
1
2024
entrez:
29
1
2024
Statut:
aheadofprint
Résumé
Brodalumab is a monoclonal antibody and IL-17 RA inhibitor that is approved for the treatment of moderate-to-severe psoriasis. The present study aims to estimate the drug survival (DS), effectiveness, and safety of brodalumab over a period of 156 weeks. The primary objectives were: (i) to determine the treatment response rate at Weeks 16, 28, 52, 78, 104, and 156 as defined by PASI100, PASI90, and an absolute PASI ≤ 3 and (ii) long-term DS. Secondary objectives included the evaluation of possible predictive factors associated with the achievement of response outcomes, and possible predictive factors associated with lower DS. The treatment response was rapid, with 80.3% of patients achieving PASI ≤ 3, 66% PASI90, and 54.3% the complete clearance of disease at Week 16. The response improved at Week 28, when a plateau was achieved with mild loss of response at later time points, in particular for PASI100 and PASI90 in 55.2 and 65.5% of patients, respectively, at Week 156. After 156 weeks of treatment, 66.22% of patients were still on therapy, and the previous use of IL-17 inhibitors appeared to be associated with an increased risk of treatment discontinuation (HR: 2.51, CI: 1.06-5.98, P = 0.037), and achievement of PASI ≤ 3 until Week 16 with less risk (HR: 0.27 CI: 0.14-0.51, P < 0.001). Bio-naïve status was favorably associated with treatment response, while high BMI negatively affected the achievement of outcomes. Our study confirms the good effectiveness and favorable safety profile of brodalumab in a real-world setting over up to 3 years of treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Brodalumab is a monoclonal antibody and IL-17 RA inhibitor that is approved for the treatment of moderate-to-severe psoriasis. The present study aims to estimate the drug survival (DS), effectiveness, and safety of brodalumab over a period of 156 weeks.
METHODS
METHODS
The primary objectives were: (i) to determine the treatment response rate at Weeks 16, 28, 52, 78, 104, and 156 as defined by PASI100, PASI90, and an absolute PASI ≤ 3 and (ii) long-term DS. Secondary objectives included the evaluation of possible predictive factors associated with the achievement of response outcomes, and possible predictive factors associated with lower DS.
RESULTS
RESULTS
The treatment response was rapid, with 80.3% of patients achieving PASI ≤ 3, 66% PASI90, and 54.3% the complete clearance of disease at Week 16. The response improved at Week 28, when a plateau was achieved with mild loss of response at later time points, in particular for PASI100 and PASI90 in 55.2 and 65.5% of patients, respectively, at Week 156. After 156 weeks of treatment, 66.22% of patients were still on therapy, and the previous use of IL-17 inhibitors appeared to be associated with an increased risk of treatment discontinuation (HR: 2.51, CI: 1.06-5.98, P = 0.037), and achievement of PASI ≤ 3 until Week 16 with less risk (HR: 0.27 CI: 0.14-0.51, P < 0.001). Bio-naïve status was favorably associated with treatment response, while high BMI negatively affected the achievement of outcomes.
CONCLUSION
CONCLUSIONS
Our study confirms the good effectiveness and favorable safety profile of brodalumab in a real-world setting over up to 3 years of treatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 the International Society of Dermatology.
Références
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373:1318-1328.
Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175:273-286.
Mease PJ, Helliwell PS, Hjuler KF, Raymond K, McInnes I. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis. 2021;80(2):185-193. https://doi.org/10.1136/annrheumdis-2019-216835
Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2020;82(2):352-359.
Galluzzo M, Caldarola G, de Simone C, Bernardini N, Moretta G, Pallotta S, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther. 2021;21(9):1299-1310.
Fargnoli MC, Esposito M, Dapavo P, Parodi A, Rossi M, Tiberio R, et al. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2021;35(3):693-700.
Tampouratzi E, Papakonstantis M, Katsantonis J, Sidiropoulos T, Delli F, Efthymiadis K, et al. Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: experience from clinical practice of four tertiary hospitals. Dermatol Ther. 2022;35(7):e15532.
Dapavo P, Siliquini N, Mastorino L, Avallone G, Merli M, Agostini A, et al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatolog Treat. 2022;33(4):2352-2357.
Kimmel G, Chima M, Kim HJ, Bares J, Yao CJ, Singer G, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81(3):857-859.
Loft N, Bregnhøj A, Fage S, Nielsen CH, Enevold C, Zachariae C, et al. Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis. Dermatol Ther. 2021;34(6):e15106.
Mastorino L, Cariti C, Susca S, Boskovic S, Aquino C, Ortoncelli M, et al. Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks. J Dermatolog Treat. 2022;33(8):3211-3213. https://doi.org/10.1080/09546634.2022.2125265
Mastorino L, Cariti C, Susca S, Siliquini N, Verrone A, Stroppiana E, et al. Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: a real-life experience on 638 patients with psoriasis [published online ahead of print, 2023 Jul 3]. Exp Dermatol. 2023;32:1591-1594. https://doi.org/10.1111/exd.14874
Greig SL. Brodalumab: first global approval [published correction appears in Drugs. 2016 Oct;76(16):1587]. Drugs. 2016;76(14):1403-1412. https://doi.org/10.1007/s40265-016-0634-8
European Medicines Agency. Kyntheum® SPC. https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum (Accessed July, 9th 2022).
Rompoti N, Politou M, Stefanaki I, Vavouli C, Papoutsaki M, Neofotistou A, et al. Brodalumab in plaque psoriasis: real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks. J Eur Acad Dermatol Venereol. 2023;37(4):689-697. https://doi.org/10.1111/jdv.18825
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, et al. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1196966. https://doi.org/10.3389/fmed.2023.1196966
Mastorino L, Dapavo P, Avallone G, Merli M, Cariti C, Rubatto M, et al. Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? J Dermatolog Treat. 2022;33(5):2495-2502. https://doi.org/10.1080/09546634.2021.1970706
Lebwohl M, Leonardi C, Wu JJ, Armstrong A, Rawnsley N, Merchant M, et al. Two-year US pharmacovigilance report on brodalumab. Dermatol Ther (Heidelb). 2021;11(1):173-180.
Avallone G, Maronese CA, Murgia G, Carrera CG, Mastorino L, Roccuzzo G, et al. Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study. J Clin Med. 2023;12(4):1662. [Published 2023 Feb 19]. https://doi.org/10.3390/jcm12041662